[CAS NO. 57477-39-1] BRL54443
PRODUCTS SPECIFICATIONS [57477-39-1]
DESCRIPTION [57477-39-1]
Overview
| MDL | MFCD01861184 |
|---|---|
| Molecular Weight | 230.31 |
| Molecular Formula | C14H18N2O |
| SMILES | OC1=CC2=C(NC=C2C3CCN(C)CC3)C=C1 |
Summary
BRL 54443 is a potent 5-HT 1E/1F receptor agonist ( K i values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors [1] .
IC50 & Target
|
5-HT 1E Receptor 1.1 nM (Ki) |
5-HT 1F Receptor 0.7 nM (Ki) |
5-HT 1A Receptor 63 nM (Ki) |
5-HT 1B Receptor 126 nM (Ki) |
5-HT 1D Receptor 63 nM (Ki) |
5-HT 2A Receptor 1259 nM (Ki) |
||
|
5-HT 2B Receptor 100 nM (Ki) |
5-HT 2C Receptor 316 nM (Ki) |
5-HT 6 Receptor >10,000 nM (Ki) |
5-HT 7 Receptor >10,000 nM (Ki) |
||||
In Vitro
Despite its low affinity for other receptors [5-HT
1A
(63 nM), 5-HT
1B
(126 nM), 5-HT
1D
(63 nM), 5-HT
2A
(1259 nM), 5-HT
2B
(100 nM), 5-HT
2C
(316 nM), 5-HT
6
(>10,000 nM), 5-HT
7
(>10,000 nM), D
2
(501 nM), D
3
(631 nM), and α
1B
-adrenoceptors (1259 nM)], BRL54443 binds with high affinity at 5-HT
1F
receptors
[1]
.
In DG membranes, BRL54443 selectively stimulates 5-HT
1E
receptors and potently inhibits forskolin-dependent cAMP production (IC
50
=14 nM). BRL 54443 also induces contraction (-log EC
50
=6.52)
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Reduction of flinching was considered as antinociception. Ipsilateral, but not contralateral, peripheral administration of BRL54443 (5-HT(1E/1F); 3-300 microg/paw) significantly reduced formalin-induced flinching in rats
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 434.20 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.3420 mL | 21.7099 mL | 43.4197 mL |
| 5 mM | 0.8684 mL | 4.3420 mL | 8.6839 mL |
| 10 mM | 0.4342 mL | 2.1710 mL | 4.3420 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.85 mM); Clear solution
References
- [1] Klein MT, et al. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-867.
- [2] McKune CM, et al. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95.
- [3] Klein MT, et al. Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study. Br J Pharmacol. 2012 Jun;166(4):1290-302.
- [4] Granados-Soto V, et al. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. Neuroscience. 2010 Jan 20;165(2):561-8.
Synonyms
